drugset
drugset / Trial / NCT01285518

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01285518 ↗

Phase 1 Completed 84 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.

Timeline

Start
2011-02
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05231023 Protein / enzyme biologic 0.5 mg Intravenous
Subject PF-05231023 Protein / enzyme biologic 1.5 mg Intravenous
Subject PF-05231023 Protein / enzyme biologic 5 mg Intravenous
Subject PF-05231023 Protein / enzyme biologic 15 mg Intravenous
Subject PF-05231023 Protein / enzyme biologic 50 mg Intravenous
Subject PF-05231023 Protein / enzyme biologic 100 mg Intravenous
Subject PF-05231023 Protein / enzyme biologic 200 mg Intravenous

Indications

type 2 diabetes mellitus